Real-time glucose data and alerts from the world’s first and only long-term CGM system can now be remotely monitored by friends and family of Eversense users on Android and iOS operating system
Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it received CE mark of the Eversense® NOW Remote Monitoring App for the Android Operating System.
The Eversense NOW iOS platform has previously been approved and is currently available in Europe.
“We’re pleased to offer yet another tool for our Eversense users in Europe, now enabling access to this important feature for all our customers,” said Tim Goodnow, PhD, President and CEO of Senseonics. “With the Eversense NOW app, Eversense users can enjoy the added peace of mind that comes with knowing friends and family can remotely view real-time glucose data, see trend graphs, and receive real-time glucose alerts from anywhere.”
The Eversense NOW Remote Monitoring app for the Android operating system is expected to be available starting in the first quarter of 2022 on the Google Play™ Store.
The Eversense® XL Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 180 days. The system is intended to complement, not replace, fingerstick blood glucose (BG) measurements for diabetes treatment decisions.
The sensor insertion and removal procedures are performed by a health care provider. The Eversense XL CGM System is a prescription device; patients should talk to their health care provider to learn more.
Source: Company Press Release